These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Aluminum and dialysis dementia. Mayor GH Ann Intern Med; 1979 Sep; 91(3):497-8. PubMed ID: 573084 [No Abstract] [Full Text] [Related]
7. [Water purification in dialysis treatment. Aluminum and encephalopathy]. Hagstam KE; Lindergård B; Lindholm T; Thysell H Lakartidningen; 1980 Jun; 77(26-27):2425-7. PubMed ID: 7401791 [No Abstract] [Full Text] [Related]
8. Aluminum in chronic hemodialysis. Possible influence on osteomalacic bone disease. Quarello F; Giachino G; Bossi P; Gilli G; Corrao G; Scursatone E; Jeantet A; Bossi R; Coppo R; Piccoli G; Vercellone A Minerva Nefrol; 1980; 27(4):635-44. PubMed ID: 7254691 [No Abstract] [Full Text] [Related]
9. [Long term CaCO3 treatment of chronic hemodialysis patients--an attempt to prevent and treat aluminum osteopathy]. Matsubara M; Totsune K; Saito T; Yoshinaga K; Unagami H; Sato H Nihon Jinzo Gakkai Shi; 1988 Nov; 30(11):1349-54. PubMed ID: 3236516 [No Abstract] [Full Text] [Related]
10. Aluminum related dialysis osteomalacia and dementia after prolonged use of the Redy cartridge. Pierides AM; Frohnert PP Trans Am Soc Artif Intern Organs; 1981; 27():629-33. PubMed ID: 7331145 [No Abstract] [Full Text] [Related]
11. Clinical aspects of dialysis dementia. Silke B; Fitzgerald GR; Hanson S; Carmody M; O'Dwyer WF Ir Med J; 1978 Jan; 71(1):10-2. PubMed ID: 624610 [No Abstract] [Full Text] [Related]
12. Dialysis encephalopathy. Alfrey AC Kidney Int Suppl; 1986 Feb; 18():S53-7. PubMed ID: 3457997 [No Abstract] [Full Text] [Related]
13. [Nervous system disorders induced by occupational exposure to aluminium compounds: a literature review]. Sińczuk-Walczak H Med Pr; 2001; 52(6):479-81. PubMed ID: 11928679 [TBL] [Abstract][Full Text] [Related]
14. Reversal of aluminum-induced hemodialysis anemia by a low-aluminum dialysate. O'Hare JA; Murnaghan DJ N Engl J Med; 1982 Mar; 306(11):654-6. PubMed ID: 7057824 [No Abstract] [Full Text] [Related]
15. Encephalopathy in chronic renal failure responsive to deferoxamine therapy. Another manifestation of aluminum neurotoxicity. Sprague SM; Corwin HL; Wilson RS; Mayor GH; Tanner CM Arch Intern Med; 1986 Oct; 146(10):2063-4. PubMed ID: 3767553 [TBL] [Abstract][Full Text] [Related]
16. [Polyneuropathy and central nervous system diseases before and after heart transplantation. Is cyclosporin neurotoxic?]. Porschke H; Strenge H; Stauch C Dtsch Med Wochenschr; 1991 Oct; 116(42):1577-82. PubMed ID: 1935623 [TBL] [Abstract][Full Text] [Related]
17. The effect of low aluminum water and desferrioxamine on the outcome of dialysis encephalopathy. Milne FJ; Sharf B; Bell P; Meyers AM Clin Nephrol; 1983 Oct; 20(4):202-7. PubMed ID: 6641027 [TBL] [Abstract][Full Text] [Related]
18. Role of desferrioxamine in the treatment of dialysis encephalopathy. Ackrill P; Ralston AJ; Day JP Kidney Int Suppl; 1986 Feb; 18():S104-7. PubMed ID: 3457985 [No Abstract] [Full Text] [Related]
19. [The deferoxamine loading test as a non-invasive method for diagnosing Al-related bone disease in hemodialysis patients; efficacy of deferoxamine therapy for the disease]. Umetani N; Sato N; Yoshida A; Marumo F Nihon Jinzo Gakkai Shi; 1988 Feb; 30(2):143-50. PubMed ID: 3386018 [No Abstract] [Full Text] [Related]